Updated Jul 16, 2026
Saggar Rajeev has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $3.20M.
Rajeev Saggar is the Chief Medical Officer at Liquidia Corp, a biopharmaceutical company focused on developing treatments for pulmonary hypertension. He has been involved in the company's operations as indicated by multiple SEC filings.
| Role | Chief Medical Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 9.2K | $71.52 | $660K |
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 703 | $71.39 | $50K |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 4.5K | — | |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 3.5K | — | |
| 2026-04-14 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 9.2K | $38.37 | $354K |
| 2026-04-14 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 4.5K | — | |
| 2026-04-14 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 3.5K | — | |
| 2026-03-17 | LQDA | Liquidia Corp | S — Open-market sale | 35.4K | $36.30 | $1.28M |
| 2026-01-21 | LQDA | Liquidia Corp | A — Grant or award | 33.0K | $0.00 | |
| 2025-10-10 | LQDA | Liquidia Corp | S — Open-market sale | 5.3K | $23.41 | $125K |
| 2025-10-10 | LQDA | Liquidia Corp | M — Option exercise | 3.5K | — | |
| 2025-08-28 | LQDA | Liquidia Corp | S — Open-market sale | 20.0K | $27.85 | $557K |
| 2025-07-21 | LQDA | Liquidia Corp | S — Open-market sale | 2.5K | $14.54 | $37K |
| 2025-07-11 | LQDA | Liquidia Corp | S — Open-market sale | 5.3K | $14.28 | $76K |
| 2025-07-11 | LQDA | Liquidia Corp | M — Option exercise | 3.5K | — | |
| 2024-10-22 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 2.5K | $11.19 | $28K |
| 2024-10-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 2.3K | $11.11 | $25K |
Rajeev Saggar is the Chief Medical Officer at Liquidia Corp, a biopharmaceutical company focused on developing treatments for pulmonary hypertension. He has been involved in the company's operations as indicated by multiple SEC filings.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 10 open-market sales ($3.20M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Saggar Rajeev profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.